Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review
Authors
Keywords
Rasagiline, Levodopa, Parkinson’s disease, Motor, Off-time, Systematic review
Journal
NEUROLOGICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-25
DOI
10.1007/s10072-019-04050-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
- (2018) Éva Szökő et al. JOURNAL OF NEURAL TRANSMISSION
- Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease
- (2018) Muhammed Khairujjaman Mazumder et al. MEDICAL HYPOTHESES
- Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia
- (2018) Venkata Sunil Bendi et al. PARKINSONISM & RELATED DISORDERS
- Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
- (2018) Zhenxin Zhang et al. Translational Neurodegeneration
- Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan
- (2018) Nobutaka Hattori et al. PARKINSONISM & RELATED DISORDERS
- Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy
- (2018) De-Qi Jiang et al. MEDICINE
- Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
- (2017) Emanuele Cereda et al. JOURNAL OF NEUROLOGY
- Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia
- (2017) Laura L. Frakey et al. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study
- (2017) Domiziana Rinaldi et al. NEUROLOGICAL SCIENCES
- Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial
- (2016) Daniel Weintraub et al. MOVEMENT DISORDERS
- Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease
- (2015) Daphne Robakis et al. CNS DRUGS
- A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients
- (2015) P. Barone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Rasagiline for the treatment of Parkinson’s disease: an update
- (2015) Fabrizio Stocchi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease
- (2015) Thien Thien Lim et al. MOVEMENT DISORDERS
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease
- (2014) Paul L. McCormack CNS DRUGS
- Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease
- (2014) Robert A. Hauser et al. MOVEMENT DISORDERS
- Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts
- (2013) Nina Kaludercic et al. ANTIOXIDANTS & REDOX SIGNALING
- Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial
- (2013) Lina Zhang et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials
- (2013) Lawrence W. Elmer PARKINSONISM & RELATED DISORDERS
- Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease
- (2011) F. Stocchi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety of rasagiline for the treatment of Parkinson's disease
- (2011) Santiago Perez-Lloret et al. Expert Opinion On Drug Safety
- The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study
- (2011) Hasmet A. Hanagasi et al. MOVEMENT DISORDERS
- Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson’s Disease
- (2011) C. Venkateshappa et al. NEUROCHEMICAL RESEARCH
- TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease
- (2009) Ken Ikeda et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain
- (2009) Orly Weinreb et al. JOURNAL OF NEURAL TRANSMISSION
- L-dopa therapy for Parkinson's disease: Past, present, and future
- (2009) Toshiharu Nagatsu et al. PARKINSONISM & RELATED DISORDERS
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started